1.80
1.09%
-0.03
Medicinova Inc stock is traded at $1.80, with a volume of 79,807.
It is down -1.09% in the last 24 hours and up +0.00% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.83
Open:
$1.79
24h Volume:
79,807
Relative Volume:
1.07
Market Cap:
$88.29M
Revenue:
-
Net Income/Loss:
$-9.51M
P/E Ratio:
-7.20
EPS:
-0.25
Net Cash Flow:
$-10.96M
1W Performance:
+18.30%
1M Performance:
+0.00%
6M Performance:
+27.46%
1Y Performance:
+1.69%
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
MNOV | 1.81 | 88.29M | 0 | -9.51M | -10.96M | -0.25 |
VRTX | 467.37 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.78 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.58 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.64 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-10-21 | Initiated | Maxim Group | Buy |
Mar-25-19 | Resumed | B. Riley FBR | Buy |
Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
Apr-18-17 | Initiated | Credit Suisse | Outperform |
Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
May-24-12 | Downgrade | MLV & Co | Buy → Hold |
Oct-18-11 | Reiterated | MLV Capital | Buy |
Jun-22-11 | Initiated | Global Hunter Securities | Buy |
May-12-10 | Initiated | Wedbush | Outperform |
Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - MarketBeat
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova: Q3 Earnings Snapshot - New Haven Register
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com
MediciNova stock hits 52-week high at $2.17 amid growth By Investing.com - Investing.com UK
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - The Manila Times
MediciNova Secures Major Settlement from Sanofi-Novartis Litigation, Boosts Clinical Pipeline | MNOV Stock News - StockTitan
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
MediciNova (NASDAQ:MNOV shareholders incur further losses as stock declines 11% this week, taking five-year losses to 80% - Simply Wall St
MediciNova (NASDAQ:MNOV) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TSX Buyback Index (TXBB) QuotePress Release - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Is Booming Worldwide - openPR
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – Should You Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Clean Harbors (CLH-N) QuotePress Release - The Globe and Mail
MediciNova Announces Update of Phase 2/3 Clinical Trial of - GlobeNewswire
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - StockTitan
MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
MediciNova, Inc. (NASDAQ:MNOV) Shares Sold by Dimensional Fund Advisors LP - Defense World
Type 1 Diabetes Market Report 2034: Epidemiology Data, Pipeline - openPR
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS - Smartkarma
MNOVMedicinova, Inc. Latest Stock News & Market Updates - StockTitan
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Rises By 19.3% - MarketBeat
MediciNova to Support NIH-Funded Expanded Access Clinical - GlobeNewswire
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - StockTitan
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average of $1.42 - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
Insigneo Advisory Services LLC Has $6.10 Million Stock Position in Mastercard Incorporated (NYSE:MA) - Defense World
Intech Investment Management LLC Takes Position in MSA Safety Incorporated (NYSE:MSA) - MarketBeat
Minerals Technologies (NYSE:MTX) Upgraded at StockNews.com - MarketBeat
Monroe Capital (NASDAQ:MRCC) Stock Crosses Above 200 Day Moving Average of $7.49 - MarketBeat
MARXU stock soars to all-time high of $12.15 amid market optimism - Investing.com Australia
Marcus (NYSE:MCS) Upgraded by StockNews.com to Hold - Defense World
Mistras Group senior EVP sells over $349k in company stock - Investing.com
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX) - Stockhouse Publishing
Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA) - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMGNX - Longview News-Journal
MasterBrand (NYSE:MBC) Hits New 52-Week High at $19.10 - MarketBeat
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Mutual of America Capital Management LLC Cuts Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):